Most Read Articles
Rachel Soon, 16 Nov 2019

The third Pharmaceutical Industry Pharmacists Insight (PIPI 3.0) symposium will highlight areas of the pharmaceutical industry often overlooked by those entering the pharmacy profession.

Jairia Dela Cruz, 23 Apr 2019
Rupatadine at either 10 or 20 mg delivers superior improvements in nasal and ocular symptoms of seasonal allergic rhinitis compared with placebo, with both doses well tolerated by adult and adolescent patients, according to the results of a phase III trial.
02 Dec 2019
Podcast: Associate Prof Pilar Garrido says osimertinib may be the best option in the first-line treatment of advanced NSCLC based on FLAURA OS results.
Pearl Toh, 20 Dec 2019
Faecal microbiota transplantation (FMT) is effective in reducing symptoms of irritable bowel syndrome (IBS), but having a “super-donor” is key, a study presented at UEG* Week has shown — highlighting the importance of donor selection for the success of FMT as a treatment for IBS.

Intraperitoneal cefepime a feasible first-line treatment in CAPD-associated peritonitis

22 Nov 2019

Use of intraperitoneal (IP) cefepime monotherapy proves noninferior to conventional combination therapy in the management of continuous ambulatory peritoneal dialysis (CAPD)-associated peritonitis, inducing resolution at day 10, according to the results of an open-label trial.

The study randomized 144 adult peritoneal dialysis (PD) patients with CAPD-associated peritonitis to receive either IP monotherapy of cefepime (1g/d; n=70) or IP combination of cefazolin plus ceftazidime (1g/d; n=74) both given as continuous dosing. Baseline demographic and clinical characteristics were similar between the treatment groups.

Resolution of peritonitis at day 10, the primary endpoint, occurred with greater frequency in the monotherapy than in the combination group (82.6 percent vs 81.1 percent; treatment difference, 1.5 percent, 90 percent confidence interval [CI], –9.1 to 12.1; p=0.04).

There was no significant between-group difference in terms of initial response rate (65.7 percent vs 60.8 percent; treatment difference, 4.9 percent, 95 percent CI, –10.8 to 20.6; p=0.5) and complete cure rate (80.0 percent vs 80.6 percent; treatment difference, –0.6 percent, 95 percent CI, –13.9 to 12.8; p=0.7).

In the monotherapy group, peritonitis relapsed in 4.6 percent of patients and recurred in another 4.6 percent as opposed to 4.2 percent and 5.6 percent of patients in the combination-therapy group, respectively (p=0.9 and p=0.8).

All-cause mortality was slightly higher in the monotherapy group (7.1 percent vs 2.7 percent; treatment difference, 4.4 percent, 95 percent CI, –2.6 to 11.5), although the difference was not statistically significant (p=0.2).

The present data suggest that IP cefepime monotherapy may be a reasonable first-line treatment alternative for patients with CAPD-related peritonitis, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 16 Nov 2019

The third Pharmaceutical Industry Pharmacists Insight (PIPI 3.0) symposium will highlight areas of the pharmaceutical industry often overlooked by those entering the pharmacy profession.

Jairia Dela Cruz, 23 Apr 2019
Rupatadine at either 10 or 20 mg delivers superior improvements in nasal and ocular symptoms of seasonal allergic rhinitis compared with placebo, with both doses well tolerated by adult and adolescent patients, according to the results of a phase III trial.
02 Dec 2019
Podcast: Associate Prof Pilar Garrido says osimertinib may be the best option in the first-line treatment of advanced NSCLC based on FLAURA OS results.
Pearl Toh, 20 Dec 2019
Faecal microbiota transplantation (FMT) is effective in reducing symptoms of irritable bowel syndrome (IBS), but having a “super-donor” is key, a study presented at UEG* Week has shown — highlighting the importance of donor selection for the success of FMT as a treatment for IBS.